The nanostructured drugs for cancer treatment that have so far reached the oncology market largely rely on passive targeting (p.e.: Abraxane, Doxil, Daunoxome, Oncaspar, DepoCyt), meaning that they are not empowered by specific mechanisms to recognize specific cell types or tissues. Preferential but still passive accumulation into tumor tissues is thus favored; in addition the increase in circu...